Kymab’s unique platforms generate a vast repertoire of fully human, species cross-reactive and affinity-matured antibodies against challenging targets. Kymab is focused on immune mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®.
Kymab, the first spin-out from The Wellcome Trust Sanger Institute, generates product candidates using its proprietary, integrated technology platform. Its IntelliSelect® Transgenic discovery platforms are designed to generate fully human monoclonal antibodies from highly engineered strains of mice that have the complete constellation of human antibody building blocks in their genome. Kymab’s development platforms combine single cell sequencing, genomics and proprietary bioinformatic algorithms to prioritise and select antibodies generated by its discovery platforms that have the most desirable druglike properties.
Together with Kymab’s antibody discovery and development expertise, Kymab’s suite of technologies has enabled the generation of a deep pipeline of product candidates and an expanding discovery pipeline, including both traditional antibodies and bi-specific antibodies.
Alongside its wholly-owned programmes, Kymab has partnered with world-leading scientific and medical collaborators, including Sosei Heptares Therapeutics and the Bill and Melinda Gates Foundation.